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Abstract
The blood-brain barrier (BBB) is the major problem for the treatment of brain diseases 
because we need to be able to deliver drugs from the vascular system into the central 
nervous system (CNS). There are no drug therapies for a wide range of CNS diseases and 
these include neurodegenerative diseases such as Alzheimer’s and Parkinson’s diseases 
and cerebral ischemia. Therefore, the focus of this chapter is to discuss how nanoparticles 
(NPs) can be modified to transport different drug molecules for the treatment of brain 
diseases. In essence, NPs’ surface can be functionalized with molecules such as peptides, 
antibodies and RNA aptamers and these macromolecules can be attached to the receptors 
present at the BBB endothelial cell surface, which allows the NPs cross the barrier and 
subsequently deliver pharmaceuticals to the brain for the therapeutic and/or imaging of 
neurological disorders. In fact, part of the difficulty in finding an effective treatment for 
these CNS disorders is that there is not yet an efficient delivery method for drug delivery 
across the BBB. However, over the last several years, researches have started to under-
stand some of the design rules to efficiently deliver NPs to the brain.
Keywords: blood-brain barrier, multifunctional nanoparticles, Alzheimer’s, Parkinson’s, 
cerebral ischemia, stroke
1. Introduction
Technological innovations, referred to as nanomedicine, is an exciting field of applications of 
nanotechnology to the diagnostic, treatment and/or prevention of traumatic injury or disease 
of the human body. This field holds the promise to deeply revolutionize the medicine to 
treatment and therapy areas such as imaging, drug delivery, cell therapy, tissue regeneration 
and development of new nanomedicine products. Due to its great importance, recent global 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
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marketed report expects that the applications of nanotechnology in medicine could reach 
$528 billion by 2019 [1]. Indeed, a broad range of nanoparticles (NPs) made of various materi-
als (e.g., polymers, dendrimers, gold, silver, lipids, metals, and virus-like particles), differing 
in their size, architecture and surface properties, has been initially engineered to improve 
parameters such as the pharmacokinetics and biodistribution of therapeutic molecules and 
to reduce drugs’ toxicity side effects [2]. Additionally, NPs are also useful tools for body or 
organ imaging [3]. During the past few decades, NPs have been successfully developed as 
drug, gene and/or imaging delivery vehicles due to their key properties of enhancing water 
solubility of poorly water-soluble molecules, extending the plasma circulation time and tar-
geting the site of disease, while avoiding nonspecific toxicity effects [4, 5].
In fact, NPs have provided remarkable progress in therapy and diagnostic imaging of sev-
eral diseases. Since 1990, a high number of nanocarrier formulations have been approved 
by regulatory authorities for clinical use [6, 7]. There are five different applications of 
nanomedicine products on the market within healthcare – in vitro diagnostics; biomateri-
als; drug delivery; in vivo imaging and active implants [7]. Of these products, the type 
of NPs that exists on the market is diverse and it includes the following: (i) liposomes 
(e.g., Ambisome®, Albelcet®, DaunoXome®, Depocyt® and Myocet®); (ii) polymer-coated 
liposomes (e.g., Doxil® and Lipo-Dox®); (iii) polymeric drugs (e.g., Copaxone®); (iv) 
polymer-protein conjugates (e.g., Oncospar®, PEG-Intron® and Pegasys®); (v) nanoparticle 
containing paclitaxel (e.g., Abraxane™), (vi) antibodies (e.g., Avastin™ and Herceptin®) 
and (vii) antibody conjugates (e.g., Mylotarg®); (viii) aptamer conjugates (e.g., Macugen®); 
(viii) micelles (e.g., Estrasorb®); among others. These formulations are considered the first 
generation of nanomedicine, already bringing clinical benefits to patients [8].
Moreover, researches are constantly focusing on the development of NPs that can accumulate 
and deliver their cargo specifically at the diseased site, and these efforts are bringing important 
advances toward the development of NP-based targeted drug delivery systems. To increase 
the specificity of NPs to the targeted area, nanocarriers that can either passively or actively 
target the unhealthy site have been engineered. In passive targeting, the capacity of NPs to 
accumulate in the angiogenic site of tumors by the enhanced permeability and retention effect 
is explored [6, 9]. This strategy is achieved by recovering surface of NPs with some sort of 
coating with several compounds such as poly(ethylene glycol) (PEG) and poly(phosphoester) 
(PEEP) [10]. By binding PEG or PEEP to the surface of NPs, there occurs a change in the pro-
tein corona populations that adhere to the surface of NPs, reducing drastically the opsoniza-
tion process of the nanocarriers thus preventing recognition by macrophages and monocytes 
and rapid clearance of NPs from the blood [10, 11]. Also, the accumulation and cellular uptake 
of NPs could be further enhanced by conjugating the NPs with molecules such as antibodies, 
peptides and aptamers that are able to bind to overexpressed receptor or antigens on the 
surface of targeted cells [12].
More recently, various researchers have been developing NPs able to perform two or more 
functions for the simultaneous or sequential delivery of single or multiple therapeutic 
active principles to the required targeted site in the body, overcoming multiple physiologi-
cal barriers [13]. Multifunctional NPs often have the ability to: (i) encapsulate sufficient 
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amount of drug or therapeutic macromolecules for a sufficient time; (ii) increase residence 
time in the blood through the use of soluble polymers such as polyethylene glycol (PEG); 
(iii) increase their accumulation at the desired site in the body by attaching to NPs, surface 
macromolecules such as antibodies, RNA aptamers and peptides; (iii) respond to several 
intrinsic or extrinsic stimuli for “on demand” delivery such as abnormal pH, temperature 
or magnetic and ultrasound fields and (iv) entrap concomitantly an imaging agent to enable 
the real-time monitoring of their biodistribution, targeted accumulation and/or therapy 
efficiency [2, 13].
Despite the exciting advances in the discipline of nanotechnology-based approaches, dif-
ferent challenges arise in their efficacy toward the treatment of neurodegenerative diseases. 
One of the major obstacles that limit the application of NPs for effective delivery of drugs 
and diagnostic imaging agents to the central nervous system (CNS) is the presence of the 
blood-brain barrier (BBB) [14]. As a result, new and innovative invasive and noninvasive NPs 
formulations have been engineered to provide efficacy in crossing the BBB, mainly by the 
functionalization of NPs’ surface with ligands. Invasive strategies show potential and are 
being explored for efficient NPs’ access to the brain. Some examples of invasive strategies are: 
convention-enhanced delivery, intracerebral or nasal injection and use of implants. With this 
in mind, it is important to understand the general concept of BBB, mechanisms of transport in 
and out of the brain and the BBB alterations in pathology.
2. BBB, general concept and the transport of drugs inside the brain
The BBB is a formidable physiological structure that acts as an effective security system for 
the brain, letting in circulating compounds that this organ needs, but at the same time, these 
cells have evolved a system of biological pumps and if these pumps recognize molecules that 
should not be on their way to the brain, they will be pumped right back out into the vascular 
system [15]. The BBB is primarily composed of brain endothelial cells, which are cells that line 
microvessels and capillaries in the brain, and these are highly specialized cells that are knit-
ted together very tightly by tight junctions, so there are no gaps between the cells (Figure 1). 
In fact, endothelial cells’ tight junctions control the flux of hydrophilic molecules and small 
lipophilic substances such as water and some gases, respectively, that go through the BBB [15, 
16]. Also, the brain endothelial cells are surrounded by a structure known as basal lamina, 
composed of fibronectin, type IV collagen, heparin sulfate and laminin [16, 17].
Other structures such as neurons, astrocytes, pericytes and extracellular matrix components 
constitute the neurovascular unit that is also part of the BBB structure (Figure 1). Neurons are 
electrically excitable cells responsible for processing and transmitting information through-
out the mind and body. In the nervous system, chemical and electrical signals between 
neurons occur via synapses, or junctions, that connect these cells [18]. Astrocytes play a key 
role in providing nutrients to neurons by shuttling them from the blood vessels to neurons 
themselves; they also help to control the ion concentration in the brain; are part of the repair 
process that happens after brain injury and help neurons recycle their neurotransmitters [19]. 
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Pericytes appear to play a key role in BBB endothelial cells barrier formation [20]. Finally, 
the extracellular matrix occupies 10–20% of brain volume and has a major role in its normal 
pathology [21]. Therefore, it is the vascular unit that controls permeability and cerebral blood 
flow throughout the CNS, ensuring physiological CNS functioning.
In Figure 1, a schematic overview of the mechanisms of transport through the BBB is depicted. 
Molecules that present either a high degree of lipophilicity and molecular weight smaller than 
500 Da can penetrate the CNS by simple diffusion (Figure 1A). However, in the absence of 
these characteristics, other circulating molecules can cross the BBB by their interaction with 
specific transport proteins located at the brain endothelial surface. These proteins are classified 
into two main categories: (i) carrier-mediated transport and (ii) receptor-mediated transport. 
Carrier-mediated transport (CTM) systems are responsible for the transport of small-drug 
molecules or small nutrient molecules including monosaccharaides and amino acids with 
a molecular mass smaller than 600 Da. These molecules can cross the BBB endothelial cells 
via active transport mediated by specific proteins (Figure 2C). The diffusion of molecules 
from the blood to the brain may be passive or active. For example, the transport of neutral 
L-amino acids such as leucine, phenylalanine and tyrosine is mediated by the large neutral 
amino acid transport (LAT1), whereas cationic amino acid transporter (CAT1) mediates the 
transport of cationic amino acids such as lysine and histidine. Other examples of transport-
ers of polar substances into the brain include the nucleoside transporter (CNT2), the glucose 
transporter (GLUT1) and the monocarboxylic acid transporter (MCT1) for nucleoside, glucose 
and carboxylic acids transport, respectively. Moreover, transporters presented at brain endo-
thelial cells’ surface are also able to expel endogenous peptides such as Tyr-Pro-Trp-Gly or a 
multiplicity of drugs from the CNS to the blood are to be mediated, respectively, by peptide 
Figure 1. The Blood-Brain Barrier. Schematic cross-sectional representation of the blood brain barrier (BBB) and other 
components of vascular unit like neurons, astrocytes, pericytes that are essential for the health function of the CNS. Also, 
depicted in the picture are the BBB mechanism of passage: (A) Water soluble agents; (B) Lipid solid agents; (C) Protein 
transport; (D) Receptor-mediated transport, and (E) Adsorptive transcytosis.
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transport system-1 or P-glycoprotein, via active efflux transport (AET). In fact, if a drug is a 
substrate of any AET protein, multidrug resistance occurs, and this phenomenon is a great 
obstacle for therapeutic drug delivery to the CNS.
Chemotherapy agents, natural, synthesized or recombinant peptides and proteins, nucleic 
acids, monoclonal antibodies and other pharmaceutical breakthroughs do not readily cross 
the BBB (Figure 2D). Nonetheless, there are some specific proteins that the brain needs to func-
tion correctly, so they can access the brain by attaching to receptors, which are transported 
across the barrier and subsequently release into the brain. This mechanism of transport is 
known as receptor-mediated transport (RMT) and the internalization of these relatively large 
compounds is done via endocytosis (Figure 2E). It is the most studied transport mechanism 
for drug delivery, since receptor-specific ligands such as peptides and antibodies against 
receptors that are expressed on brain endothelial cells surface can be attached to the surface 
of nanoparticles or drugs, enabling their accumulation and internalization by cells of vascular 
side and, consequently, being transported into the brain. In addition, adsorptive-mediated 
Figure 2. Schematic representation of a drug-loaded, multifunctional, stimuli-responsive NP. The structure of a 
nanocarrier allows the incorporation of one or multiple therapeutic molecules. These NPs can be found in different sizes 
and shapes. Increased blood circulation time can be achieved with soluble polymers such as polyethylene glycol (PEG). 
Nonspecifically target the intended site of action can be achieved by exploring, for example, leaky vessels of tumors. 
NPs can be actively targeted via the attachment of targeted-specific ligands such as antibody, antibody fragments, 
aptamers and peptides at their surface. Depending on the kind of application of NPs, various compounds can be added 
to turn the nanocarrier into a responsive device to a specific stimuli such as temperature, pH or magnetic and ultrasound 
fields. Imaging or contrast agents such as magnetic resonance imaging (MRI) , near infrared (NIR)  and/ or polyethylene 
terephthalate (PET) compounds can also be incorporated into a single platform to enable imaging and releasing of drugs 
from NPs.
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transport (AMT) is a kind of transport where endocytosis is induced by the binding of cationic 
substances to the negatively charged plasma membrane of brain endothelial cells interaction. 
Therefore, due to the electrostatic interaction between the negatively charged membranes, the 
cationic therapeutic compound takes the AMT to enter the CNS.
This becomes a problem when treating diseases of the brain because we need to be able to 
deliver drugs from the vascular system into the CNS [22]. Unfortunately, at the moment, 
there are no drug therapies for a wide range of CNS diseases, and these include neurode-
generative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD) and 
cerebral ischemia (or stroke). Therefore, the objective of this chapter is to discuss how NPs 
can be modified to transport thousands of different drug molecules for the treatment of 
brain diseases. In essence, NPs for drug delivery into the brain is a method for transport-
ing drug molecules across the BBB using nanocarriers. NPs, surface can be functionalized 
with molecules such as peptides, antibodies and RNA aptamers, and these macromolecules 
can be attached to the receptors present at the BBB endothelial cell surface, which allow 
the NPs across the barrier and subsequently deliver pharmaceuticals to the brain for the 
therapeutic and/or imaging of neurological disorders [14]. In fact, part of the difficulty in 
finding an effective treatment for these CNS disorders is that there is not yet an efficient 
delivery method for drug delivery across the BBB. However, over the last several years, 
researches have started to understand some of the design rules for efficient delivery of NPs 
to the brain.
3. In vitro approaches to study NPs’ transport through the BBB
As mentioned earlier, the BBB is a selective and dynamic barrier restricting the passage of 
a huge variety of compounds across this barrier, which is essential for the maintenance of 
homeostasis and functionality of the CNS. Therefore, the BBB is considered the major obstacle 
for the use of NPs as delivery systems to brain diseases. As shown in Figure 2, endothelial 
cells of the cerebral microvasculature are associated with perivascular cells form the BBB. The 
functional interaction between endothelial and perivascular cells and their response to injury 
have led to the concept of the neurovascular unit [15, 17]. Studying the mechanisms of uptake, 
transport and cytotoxicity of NPs through the BBB is an extremely challenging task in vivo 
because of the technical limitation to access the interface between the vascular system and the 
brain, since it is estimated that the brain capillary length is about 650 km [23]. To overcome 
this problem, in vitro BBB models have been built to reproduce as precise as possible the 
major BBB features, allowing investigation of cellular and molecular mechanisms that occur 
in the barrier; prediction of the transport of compounds across the BBB and performing high-
throughput platform to test NPs transport through the barrier for the effective treatment of 
brain diseases. For example, it was observed that NPs can reach the capillaries into the brain 
of rats or mice 30 m after intravenous injection and, up to 5 h after NPs administration, they 
could go through the barrier, decreasing afterward [24–29]. These studies of NPs across the 
brain tissue are in line with in vitro BBB models data reported [30, 31]. In addition, it was 
observed that in vitro BBB model facilitates the manipulation of some parameters that affects 
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the barrier such as aglycemia, hypoxia, among others [32]. For decades, two-dimensional 
or three-dimensional in vitro models of BBB have been developed by cultivating either as a 
monolayer or in cocultivation with mouse brain microvascular endothelial cells and murine or 
human endothelial cells with pericytes or astrocytes or glial tissue among others in a way that 
mimics the barrier under physiological or pathological conditions such as Alzheimer’s and 
Parkinson’s diseases or stroke [33–37]. Models of BBB based on stem cells are also reported 
in the literature [38, 39]. Moreover, by taking permeability measurements on the cultured 
cells, it is possible to test the physiological relevance of the developed model. In addition, 
experiments such as gene expression analysis using real-time polymerase chain reaction 
(PCR), permeability analysis [40, 41] and immunocytochemistry can also be used to validate 
the BBB model obtained. Although we are still not able to make this platform available both 
in academic and industry setting, this kind of technology has been showing the importance 
of considering in vitro data together with in vivo studies to understand the transport process 
of NPs into the brain.
4. Other barriers that limit effective drug delivery into the brain
In addition, the BBB is not the only physiological barrier for drug delivery to the brain. If we 
consider the anatomic aspects of our body, the brain and the spinal cord are completely cush-
ioned and protected by the cerebrospinal fluid (CSF) [42, 43]. This fluid is also responsible for 
carrying nutrients to and waste products away from the brain. The great majority of CSF is 
produced within ventricular areas of the brain, as a result of the specialized tissue known as 
choroid plexus. The choroid plexus is located in each of the four ventricles within the brain 
area: two lateral ventricles, and the third and fourth ventricles. Here, it is important to clarify 
that the cells of the choroid plexus do not produce the CSF; instead, this fluid is a filtrate of the 
blood that is performed by the highly specialized cells of choroid plexus known as cuboidal 
epithelial cells. Cuboidal epithelial cells are exactly located between the capillary and the 
ventricle. As all capillaries present within the brain, the capillaries of the choroid plexus have 
a wall formed by single cells responsible for ready transportation of ions and molecules to 
and from the choroid plexus capillary. Tight-gap junctions hold the choroid plexus epithelial 
cells together. These gap junctions prevent substances from entering or leaving the CSF; thus, 
the choroid plexus acts as a blood-CSF barrier. Lastly, although the CSF originates in the 
ventricles, this fluid flows through to the ventricles and then surrounds the brain and the 
spinal cord.
5. NPs for brain drug delivery
Over the last several years, researches have engineered a variety of NPs that can potentially 
deliver therapies and/or imaging agents directly into the brain [14, 42, 44–48]. It is really chal-
lenging to get these nanoparticles across the BBB to treat a CNS disease in sufficient amount 
and without causing major side effects on healthy brain cells. NPs are available in many sizes 
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and shapes and they can have a positive, negative or neutral surface charge (Figures 2, 3). Their 
core can be made of a variety of materials such as biological, synthetic or energy receptive. NPs 
can also be coated with specialized molecules that allow them to interact with their environ-
ment. NPs can also be loaded with therapeutic molecules that are released in a controlled way 
and, at the same time, retain the drug stability and prevent them from degradation once in the 
blood. Therefore, for an efficient drug delivery into the CNS, it is very important to engineer 
NPs with the following properties: (i) small size (NP diameter should be smaller than 100 nm); 
(ii) biocompatible, biodegradable, nontoxic and noninflammatory; (iii) prolonged circulation 
time in the body; (iv) stable in the plasma; (v) protect the cargo such as small molecules, pep-
tides [43, 49–51], proteins or nucleic acids from degradation; (vi) targetability to the BBB and 
(vii) controlled drug release [44].
One of the most important and challenging characteristics in engineering NPs is their func-
tionalization. Active targeting of NPs can be achieved by attaching onto their surface, in a 
highly controlled way, specific molecules such as monoclonal antibody, RNA aptamers, 
transferrin, lactoferrin and peptides (Figure 2). An example of such active NP is the extensive 
Figure 3. Types of nanoparticles for brain delivery. Enhancing brain drug delivery with the use of several nanocarriers, 
able to carry the most diverse kind of molecules.
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use of cell penetrating peptides such as SynB vectors, Tat and penetratin that were success-
fully used to target the BBB [52–55]. In fact, a huge variety of molecules that increased tar-
geting strategies to the BBB such as growth factors (e.g., vascular endothelial growth factor; 
epidermal growth factor) [56], albumin [57], insulin [58], lactoferrin [59], transferrin [60], 
angiopep-2 [61] and biotin-binding proteins has been reported [62]. Targetability is usually 
associated with nanoparticles with prolonged circulation time. This characteristic is achieved 
by coating the surface of NPs with hydrophilic polymers such a polyethylene glycol (PEG), 
poly(acryloylmorpholine), poly-N-vinylpyrrolidones, polyvinyl alcohol and poly[N-(2-hy-
droxypropyl) methacrylamide] [63] (Figures 2, 3). Among these polymers, PEG is still the 
most useful polymer in obtaining long circulating NP. The attachment of polymers onto the 
surface of NPs works by preventing NPs interaction with opsonins present at the plasma and, 
in this way, impeding their capture and subsequent clearance from the body. However, it 
was observed that the blood clearance phenomenon is accelerated after repetitive administra-
tion of clinically used PEGylated NPs due to the induction of production of antibodies (the 
NPs used in these studies were PEGylated liposomes) [64, 65]. Moreover, PEGylated NPs are 
particularly useful for neurological disease treatment, since the long-circulating NPs into the 
brain by diverse mechanisms were observed. Nevertheless, for brain tumors, reliance on the 
enhanced permeability and retention (EPR) effect for drug delivery strategies faces several 
challenges, since the accumulation of NPs at the tumor site is very low [66].
Due to their ability to carry hydrophilic, hydrophobic and/or lipophilic compounds and 
high specificity, the use of NPs provides a very efficient platform for drug delivery into the 
CNS. The most popular nanocarrier studied for brain drug delivery is liposomes and several 
liposomal formulations are clinically available or tested at different clinical trial phases [14]. 
Liposomes are spherical concentric vesicles, consisting of at least one lipid bilayer, enclos-
ing an aqueous compartment. This nanocarrier has been employed for therapeutically active 
compounds delivery soon after its discovery by Bangham in the early 1960s. This NP has been 
successfully engineered for a variety of brain neurodegenerative disorders and brain tumors. 
For a detailed overview of liposome-based strategies to drug delivery across the BBB, we refer 
the reader to Vieira and Gamarra’s article [14].
One of the breakthroughs of nanoparticles formulations is to target the nanocarriers to deliver 
their cargo into the brain. The brain endothelial cells contain several targets as discussed 
earlier that are explored on the studies of nanoparticles for brain delivery. Each of these 
targets could be specific for a brain disease or brain diseases. For example, transferrin has 
been described as the BBB-targeting ligand in studies of nanoparticle formulations [67, 68]. 
Transferrin is a glycoprotein (80 kDa) that binds to the transferrin receptor and is taken across 
the BBB via Receptor mediated endocytosis (RME). Indeed, these studies demonstrated that 
transferrin conjugated to liposomes exhibited a significant increase in the concentration of 
therapeutic molecules delivered by NPs into the brain when compared to the administration 
of the drug alone. In addition, broad ranges of nanocarriers with different shapes, sizes and 
surface properties have been developed for the transport of therapeutic or imaging molecules 
across the BBB. These also include carbon nanotubes [69, 70], micelles [71], dendrimers [72, 
73], nanofibers [74, 75], polymer [46, 76], gold [77] and iron oxide nanoparticles [78] NPs 
(Figure 3).
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Although nanotechnology-based strategies to get into the brain have shown progress in 
animal models, the translation of passive- and active-targeting delivery strategies into clini-
cal studies is still questionable. This might be due to the random nature of receptor-ligand 
interactions and/or ineffective release of drug from the nanocarrier at the targeted site [79]. 
Therefore, the development of multifunctional nanoparticles is becoming possible due to the 
engineering of stimuli-responsive systems that are able to control the release of their cargo 
and drug distribution in response to specific stimuli such as magnetic field, light, changes in 
pH, variations in temperature, among others (Figure 2).
6. NPs in context of brain neurological diseases
Getting NPs into CNS is not an easy task. As discussed earlier, the BBB is the main struc-
ture responsible for brain protection and homeostasis. In addition, it is important to men-
tion that in neurological diseases, several impairments of this structure occur, leading to the 
perpetuation of the inflammatory cycle that damages neuronal cells and neurodegeneration 
[80] Moreover, the BBB breakdown can occur, which is clearly a consequence of an ischemic 
stroke that occurred [81] due to an obstruction within a blood vessel that supplies the brain 
with oxygen and several nutrients, leading to brain cell death.
In other cases, especially in chronic neurological diseases such as Alzheimer’s disease (AD) 
and Parkinson’s disease (PD), it remains unclear how these diseases promote the BBB impair-
ment [32]. Importantly, these modifications in the BBB structure should be taken into con-
sideration when you are planning the engineering of effective multifunctional NPs for brain 
delivery. In this context, NPs have been designed to cross the BBB and this new technology 
has some applications so far in the treatment of Alzheimer’s and Parkinson’s diseases, stroke 
and brain tumors, which are discussed in the following section.
6.1. Stroke
Stroke is a serious disease that occurs when some or all of the blood supply to a part of the brain 
is restricted or cut off and, therefore, this can lead to disability, brain injury or death. Thus, the 
loss of oxygen and nutrients provided by the blood causing the loss of brain function is a stroke 
also known as cerebral ischemia. There are two ways to disturb the blood supply to the brain 
(Figure 4). The most common type occurs when there is a stoppage of blood flow to a part of the 
brain due to a blood clot. This cause of strokes accounts for 85% of all cases and it is known as 
ischemic stroke. The second cause of stroke, that is not as common as the ischemic stroke, but still 
very serious, happens when one of the blood vessels that is a part of the cerebral circulation sup-
plying the brain ruptures. This kind of stroke is called a hemorrhagic stroke. In addition, “hemor-
rhagic” refers to a sudden torrential bleeding outburst. However, regardless of whether it is an 
ischemic stroke or a hemorrhagic stroke, the brain cells start to malfunction after some minutes 
due to the lack of oxygen and nutrients owing to improper blood flow or improper blood supply.
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There is also a related condition called the transient ischemic attack (TIA), also known as 
a mini-stroke. It is essentially a temporary interruption of blood flow to a part of the brain 
often lasting between 30 m and several hours. Therefore, the symptoms of TIA and stroke are 
similar. However, the difference is that a TIA does not actually destroy brain cells and it does 
not cause permanent disability. Nevertheless, it is often a warning signal that an individual 
is at risk of having a stroke in the near future. One of the key differences is that a TIA will 
resolve, whereas, if an individual has a stroke, he/she may not gain normal functioning again 
for weeks or months, or maybe even for the rest of his/her life.
Figure 4. Schematic representation of the main event causing ischemic stroke, Alzheimer’s and Parkinson’s disease. 
(Adapted from Alvarim et al. [82]) ischemic stroke is caused by the interruption of the blood flow, depriving the 
brain of oxygen and some nutrients. For Alzheimer’s disease, the main characteristic of this disease is the presence of 
neurofibrillary tangles and amyloid plaques in the brain, leading to shrinkage of some structures of the brain such as 
the hippocampus and the enlargement of the brain ventricles, resulting in neurodegeneration. In Parkinson’s disease, 
substantia nigra dopamine neurons are lost.
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Nevertheless, the cellular and molecular mechanisms of a stroke episode have been very 
well known due to the development of several experimental animal models of ischemic 
stroke [83]. From the studies with these animal models, it was observed that during ischemic 
stroke, first occurs the opening of the BBB for a short time period. Then, occurs a refrac-
tory interval, followed by a reopening of the BBB, but this time for a long period [84] The 
reopening of the BBB is the step responsible for the activation of the endothelium, leukocyte 
recruitment, reactive oxygen species (ROS) and cytokine productions and edema formation 
[85], leading to an inflammatory response and the BBB breakdown and cell death upon 
stroke [86]. Moreover, dysregulation of tight-junction proteins is also observed during isch-
emic stroke, due to their degradation by matrix metalloproteinases, which are involved in 
the process of BBB extracellular degradation, leading to an increase in the permeability of 
the brain structure [32].
Therefore, besides the BBB itself being an excellent target for itself for treating ischemic stroke, 
the design of effective drug delivery systems has also to take into consideration the cellular 
and molecular mechanisms described earlier. One of the strategies described in the literature 
to overcome neuronal tissue damage after a stroke event is the use of multifunctional NPs 
to deliver neuroprotective drugs into the brain, since the majority of neuroprotective drugs 
do not cross the BBB in their free form. For example, the inactive caspase-3 activation in the 
brain cells likely decreases the probability of brain cell damage after a stroke event. Although 
it was shown that some peptide inhibitors of caspase are effective compounds in promoting 
neuroprotection, they cannot readily cross the BBB. For this purpose, a positively charged NP 
of chitosan conjugated with transferrin receptor was designed to deliver the relatively specific 
caspase-3 inhibitor N-benzyloxycarbonyl-Asp(OMe)-Glu(OMe)-Val-Asp(OMe)-fluoromethyl 
ketone (Z-DEVD-FMK) across the BBB [36]. By clearly reducing the caspase 3-activity in vivo, 
this formulation was also readily transported across the BBB (less than 1 h) and it decreased 
neurological deficits and the infarcted area, proving to be a very promising formulation [27].
In the same way, several other compounds have been described to provide neuroprotection 
and to prevent neurodegeneration. One of these compounds is the Tanshinone IIA that has 
demonstrated neuroprotective effects against ischemic injury [87]. However, its use in the 
treatment of this disease is limited due to the compound’s low solubility in aqueous medium, 
short-half circulation in the plasma and inability to cross the BBB. To overcome these limita-
tions, Tanshinone IIA was successfully conjugated to PEGylated-cationic bovine serum albu-
min. These nanoparticles were able to cross the BBB in vivo, as a significant decreasing in the 
infarcted volume was observed. In addition, a reduction in the neutrophil infiltration and 
neuronal apoptosis was observed [88]. The authors also explored the molecular mechanisms 
by which this formulation conferred neuroprotection. It seems that the mechanism of action 
of this formulation in the brain is related to the down-regulation of pro-inflammatory cyto-
kines (mainly IL-8 and TNF-α), to the up-regulation of anti-inflammatory cytokines (mainly 
transforming growth factor-β1 and IL-10) and to the reduction or inhibition of mRNA and 
proteins (mainly GFAP, MMP-9, COX-2, p38MAPK, ERK1/2 and JNK) [88].
As a last example, adenosine is also a powerful molecule that has demonstrated neuroprotec-
tion to the brain after an ischemic stroke event. This molecule also presents as limitations 
short-life time in the plasma and inability to cross the BBB. Here, adenosine was conjugated to 
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the lipid-squalene and, then, yielded negatively charged NPs, showing promising results [89]. 
In vivo experiments showed that this formulation was able to extend adenosine circulation 
time in the plasma, interact with the neurovascular unit, enhance animal neurological deficit 
scores and decrease the size of the infarcted area [89].
6.2. Alzheimer’s disease
It has been estimated that AD, only in the USA, affects over 5.5 million people. Moreover, 
Alzheimer’s AD is the most common cause of dementia [90]. Dementia is a serious brain 
disease that has as major symptoms deterioration in memory, behavior and thinking. In 2015, 
dementia affected 47.5 million people worldwide. Most were over the age of 60. The United 
States data related to AD account that this disease was the sixth highest cause of death in 2005. 
It was also observed that 1 in 3 seniors who died had AD or other kinds of dementia. It is also 
expected that the number of people with Alzheimer’s will grow as the population of those 
over the age of 65 rises. In 2015, Alzheimer’s disease and other dementia cost the nation $226 
billion and by 2050 this may rise to $1.1 trillion [90].
AD was named after the German physician Dr. Alois Alzheimer who presented a case his-
tory before an important medical meeting. In 1901, he was closely following a 51-year-old 
woman patient with a mental disorder, the manifestations of which were language problems 
and memory loss. After her death, Dr. Alzheimer took a serious examination of her brain 
and found the presence of plaques and tangles that today characterize AD [91]. This dis-
ease accounts for about 60–80% of the dementia cases. In most cases, Alzheimer’s clinical 
manifestations first appear after the age of 65. However, Alzheimer’s disease is not considered 
normal aging although the greatest risk factor of developing the disease is increased age. This 
is actually the greatest known risk factor for developing AD. However, as mentioned earlier, 
Alzheimer’s is not a normal part of aging. It was observed that a greater proportion of patients 
over 85 years have AD compared to those over 65 years as AD is more likely to affect older 
individuals. Dominant genes that are transmitted through generations cause less than 5% of 
Alzheimer’s. However, family risk is the second biggest factor for the development of AD 
after a certain age. In these families, individuals usually present symptoms of Alzheimer’s 
before the age of 65 and these symptoms sometimes appear in their 30s. This form of AD 
that is hereditary and marked by Alzheimer’s symptoms at an early age is called early-onset 
familial Alzheimer’s disease (EOFAD). To date, mutations in presenilin (PS1 on chromosome 
14 and PS2 on chromosome 1) and the amyloid precursor protein gene (APP) on chromosome 
21 have been associated with EOFAD. All these three gene mutations (PS1/PS2/APP) affect the 
pathway in amyloid precursor protein synthesis, which leads to the increase of production of 
Aβ, creating plaques in the brain [92]. Additionally, there are certain genes such as apoE gene 
on chromosome 19 that increase the susceptibility to AD. There are three forms of the apoE 
gene: APOE2, APOE3 and APOE4, the last one being the one associated with a high risk for 
developing AD. Actually, an individual with two copies of this gene is at three to eight more 
risk than people with one copy of this gene.
The human brain contains about 100 billion neurons that communicate to one another via 
synapses, when a burst of chemicals called neurotransmitters are released [93]. The neu-
rotransmitters are synthesized into the synaptic gap. Then, neurotransmitters move across 
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these synaptic gaps between neurons and bind to receptor sites on the dendrites of the next 
neuron. Unfortunately, neurons are the type of cells affected by AD. To date, scientists still do 
not know exactly the causes of AD and how this process begins. However, according to recent 
studies, it appears to be likely that astrocytes’ activation contributes to the neuroinflamma-
tory component responsible for the damage of neurons decades before the issue becomes 
obvious [94].
Abnormal structures called β-amyloid plaques and neurofibrillary tangles are classical bio-
logical hallmarks of the disease [91]. The formation of extracellular β-amyloid plaques occurs 
when amyloid precursor protein in the neuron cell membrane is cleaved at different positions, 
releasing small fragments called amyloid β (Aβ) that are highly toxic to the neurons and also 
interfere with the function of the brain cells [95]. Neurofibrillary tangles, on the other hand, 
are aggregates of hyperphosphorylate of a microtubule-associated protein known as tau. Tau 
protein, which in normal cells is responsible for helping nerve cells transport nutrients and 
maintain their proper shape, is altered in AD and, as a consequence, the transport of nutri-
ents and other essential supplies into the neuron is affected, causing its death. At the same 
time, the health neurons start working less effectively. After some time, these neurons start 
losing their capacity to function and communicate to one another and, eventually, they die. 
Then, the harm may spread to structures in the brain such as hippocampus and entorhinal 
cortex, which are crucial areas of the brain responsible for forming new memories, thus caus-
ing memory loss. As neurons continue to die, affected areas of the brain begin to shrinks and 
brain functions are lost (Figure 4).
The BBB impairment in AD has been controversial [96]. However, several studies carried out 
in AD patients or AD animal models have been suggesting that the cause of cerebrovascu-
lar alterations in the BBB of the diseased brains is the accumulation of Aβ peptide [97–99]. 
Nevertheless, there are also studies suggesting that the BBB impairment is the cause of neuro-
degeneration, since the dysfunction of the brain structure in AD animal models was observed 
before Aβ aggregates were accumulated [100]. In any case, both hypotheses for the dysfunc-
tion of the BBB consider as a secondary event the tauopathies. However, a study reported that 
the tau filaments alone are able to start the disruption of the BBB and when it was deregulated, 
the BBB integrity was recovered [101].
Currently, there are no drug treatments that can cure AD. For this reason, approaches for 
treating AD are focused more on therapeutic interventions that alleviate symptoms, slow 
down or delay the progression of the disease, improving the patient’s quality of life. To date, 
there are two types of medications for Alzheimer’s treatment: acetylcholinesterase inhibitors 
(Aricept, Reminyl, Exelon and Cognex) and N-Methyl-D-aspartate (NMDA) receptor antago-
nist (Namenda). Nevertheless, the administration of these therapeutic molecules is associated 
with severe side effects. Thus, it would be desirable to develop drugs that can efficiently 
deliver these drugs into the brain. Moreover, there are also several studies showing that 
neuroprotective peptides might be an excellent compound for AD therapy, since they have 
shown to be able to break down and degrade Aβ plaques.
Multifunctional NPs are a good option to carry these peptides, since nanocarriers can protect 
them from degrading into the plasma by proteolytic enzymes and increase their stability in the 
Molecular Insight of Drug Design104
serum. For example, PEG-PLA NPs were able to protect the neuroprotective peptide NAPVSIPQ 
from degradation. However, just NPs modified with B6 peptide (similar to transferrin) were 
able to cross the blood-brain barrier in mice and successfully deliver the neuroprotective pep-
tide into the brain [102]. Moreover, it was observed that the treatment with this formulation 
improved cholinergic function and ameliorated spatial learning of AD mouse model [102]. In 
the same way, the nerve growth factor (NGF) has also been explored as a good drug for treat-
ing AD, although it is not able to cross the BBB. For this purpose, NGF was encapsulated into 
PBCA NPs, decorated with polysorbate 80 [103]. These NPs presented very promising results, 
since they were able to reach the mice brain parenchyma in less than 1 h after administration 
and these nanocarriers also proved to be able to improve recognition and memory of mice and 
to reduce by almost 40% the PD symptoms such as rigidity, tremor and oligokinesia in animal 
models [103]. Coenzyme Q10, a powerful antioxidant macromolecule, has also been explored 
at AD therapy. In this way, this coenzyme was encapsulated within PLGA NPs decorated 
with trimethylates chitosan. The results showed that these nanoparticles were able to cross 
the BBB and accumulate in the choroid plexus, ventricles and cortex. Moreover, the authors 
also observed an improvement in the cognitive and spatial memory performance of AD mice 
models and a significant reduction of senile plaques and levels of ROS [104].
6.3. Parkinson’s disease
After Alzheimer’s, PD is the second most common disease in terms of neurodegenerative dis-
eases. As the aging population increases, the number of people with this disease is expected to 
rise. It affects 0.3% and 1% of the population worldwide over the age of 40 years and 65 years, 
respectively. Pathologically, PD is characterized by progressive loss of muscle control, which 
leads to tremor of hands, bradykinesia, rigidity and postural instability [105] Motor impair-
ment in PD can also cause hypomimia, which is the decreased degree of facial expression. 
Dysphagia and hypophonia, which are disruption of the swallowing process and lack of 
coordination in the vocal musculature, are also common features in PD. Other symptoms 
also include ophthalmologic complaints such as blurred vision and gate. It is important to 
mention that all these signs and symptoms are a result of affected areas that occur within the 
brain, especially in an area known as basal ganglia [105].
Thus, PD is a result of problems that occur within the basal ganglia. The basal ganglia is a 
collection of nuclei located deep beneath the cerebral cortex and it is responsible for the correct 
execution of voluntary muscle movements and learned movement patterns. The components of 
basal ganglia are caudate nucleus and putamen (dorsal striatum); nucleus accumbens and olfac-
tory tubercule (ventral striatum), ventral pallidum, globus pallidus, subthalamic nucleus and 
substantia nigra. In PD, the basal ganglia is disrupted, causing degeneration of dopaminergic 
neurons located at the substantia nigra. Essentially, it is considered a disease of the basal ganglia 
because what happens is that when the cerebral cortex wants to initiate a movement, the basal 
ganglia receives these signals and sends it back the motor cortex via the thalamus. Through 
various pathways, the substantia nigra is connected with nuclei in basal ganglia. The basal gan-
glia plays an essential role in integrating multiple input signals to modulate the output of the 
motor cortex. Inhibitory or excitatory connections can occur in this process. Thus, the loss of 
dopamine from substantia nigra in this process underlies the symptoms described earlier [105].
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At the beginning, researches believed that the BBB did not suffer any kind of alteration during 
the disease development [106]. Surprisingly, tracking compounds such as [11C]-verapamil and 
benserazide in the brain of PD patients or PD animal models, it was observed that the con-
centration of these compounds in the brain was increased, what does not happen in the brain 
of health patients or animals since these drugs are not able to cross the BBB [107]. In addition 
to this, a good correlation between the albumin ratio and progressive BB integrity loss in the 
brain of patients with PD was observed [107]. Moreover, other signals of the BBB impairment 
such as vascular alterations and blood flow deficiencies were reported [108]. Most important, 
the increased expression of vascular endothelial growth factor (VEGF) was directly correlated 
with the high amount of blood vessels presented in the damaged dopaminergic neurons in 
the brain of monkeys [109]. Later, it was observed that the injection of VEGF into the substan-
tia nigra in the brain of rats disrupted the BBB, leading to a strong inflammation response 
and loss of dopaminergic neurons [110]. Lastly, alpha-synuclein aggregates are the central 
hallmark of PD and their accumulation seems to be correlated with the downregulation of 
the P-glycoprotein (Figure 4) [111]. Moreover, higher concentration of some metals like iron 
was found in the brain of PD patients and PD animal models because of the higher levels of 
lactoferrin receptor in the substantia nigra dopaminergic neurons of the diseased brain [32].
Currently, there is no cure for PD. However, there are drugs that work to decrease and relieve 
the symptoms of PD and maintain the quality of life of the patient. The most effective treat-
ment for PD is the use of the drug levodopa—also called L-dopa—or dopamine that is both 
able to restore or increase the concentration of dopamine in the basal ganglia. But here, we 
want to discuss an article that explored the increased expression of lactoferrin in some region 
of the brain in PD patients [112]. In this way, a PAMAM and PEG NPs were developed, coated 
with lactoferrin to the delivery of a plasmid of human glial cell line-derived neurotrophic 
factor plasmid (GDNF), since GDNF is a promising factor in treating PD, but as all plasmids 
are unable to cross the BBB. These multifunctional nanoparticles were able to not only cross 
the brain barrier but also effectively deliver the plasmid into the brain, since a neuroprotective 
effect on dopaminergic neurons and improvement of locomotor activities in AD animal mod-
els was observed [113]. Another example is the encapsulation of urocortin (hormone-related 
peptide) in PEGylated-PLGA NPs covered by lactoferrin. From the results presented, this 
formulation was able to quickly cross the BBB and to promote protection to the dopaminergic 
neurons and improve locomotor functional deficits [114].
7. Conclusions
Nanotechnology in the field of medicine has brought a variety of new ways to treat and/or detect 
diseases [13, 115, 116]. Currently, engineered pharmaceutical NPs demonstrated abilities such as 
long blood circulation time in the body fluids for their accumulation at disease sites with leaky 
vasculature [117]; specific targeted drug delivery to the pathological area due to the surface func-
tionalization of NPs with ligands such as antibodies [118]; contrast properties due to their unique 
capacity of carrying contrast agents allowing their tracking in vivo [119]; drug delivery from the 
particles responsive to a specific stimuli [79] and others. The tremendous advances in nanomedi-
cine during the past decade have significantly advanced on the engineering of nanoparticles that 
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combine several of these characteristics, known as multifunctional NPs. Long-circulating and 
target-specific NPs capable of prolonged circulation time in the blood and targeted delivery of 
drug to the brain and in vivo imaging represent one example of a multifunctional nanocarrier [44].
Moreover, we hope this chapter was a bridge between nanotechnology and central nervous sys-
tems disorders, since multifunctional NPs have a great potential in the treatment of neurological 
disorders in the near future [14, 44, 120]. However, as discussed, the BBB is one of the major 
obstacles to the delivery of drugs into the brain and, consequently, for the treatment of neuro-
logical diseases [48, 121]. The BBB is composed of very tightly connected endothelial cells and 
a variety of transporters [15, 17, 120, 122]. This results in a highly selective permeability barrier 
that separates the circulating blood from the cerebral parenchyma, thus limiting the entry of 
drugs into the brain. As discussed earlier, several multifunctional NPs for delivering therapeutic 
and/or imaging molecules into the brain have been developed [44, 47, 123]. Thus, this part of 
the chapter was organized in a way to carry the reader through the fundamentals of common 
neurological diseases such as Alzheimer’s, Parkinson’s and cerebral ischemia and their potential 
treatments with these kinds of NPs [44, 68, 88, 102, 124–139]. The purpose was to analyze some 
of the major scientific data indexed in PubMed, Web of Science and Scopus to explore different 
approaches engineered to transport and deliver imaging or therapeutic molecules to the brain by 
using multifunctional NPs technology. In this way, our gathered data on different strategies for 
the delivery of drugs across the BBB using multifunctional NPs were reviewed, discussed and 
grouped in self-explanatory figures. Results of our analysis from some research articles on our 
search showed that several strategies have been used to deliver several therapeutic compounds 
to the brain by these NPs. Functionalization of the surface of these NPs by covalent ligation of 
macromolecules such as antibodies, RNA aptamers as well peptides is an effective method for 
receptor targeting nanocarriers, which allows their BBB-penetration and the efficient delivery of 
their cargo specifically to the disease site. Additionally, methods for the development of multi-
functional NPs that can respond to external stimuli were employed, concluding that the devel-
opment of multifunctional NPs for treating neurological disorders still is at its infancy, although 
these systems have a huge chance to revolutionize the ways that brain diseases are treated.
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